原发性进行性多发性硬化症患者循环树突状细胞成熟异常。
Altered maturation of circulating dendritic cells in primary progressive MS patients.
作者信息
López Cristina, Comabella Manuel, Al-zayat Hammad, Tintoré Mar, Montalban Xavier
机构信息
Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron, HUVH, Barcelona, Spain.
出版信息
J Neuroimmunol. 2006 Jun;175(1-2):183-91. doi: 10.1016/j.jneuroim.2006.03.010. Epub 2006 May 15.
We investigated the phenotype and frequency of circulating myeloid dendritic cells (MDC) and plasmacytoid DC (PDC) in 86 multiple sclerosis (MS) patients and 33 healthy controls (HC). The MS group comprised 20 patients with primary progressive MS (PPMS), 20 patients with secondary progressive MS (SPMS), and 46 patients with relapsing-remitting MS (RRMS) [23 treated with interferon-beta (IFN-beta)]. The frequency of circulating MDC and PDC, and the expression of CD83, CD123, CD80, CD86, and CD40 were analyzed by flow cytometry. The percentage of circulating MDC was decreased in patients with SPMS and PPMS. The expression of CD83, CD80, and CD86 was lower in PPMS patients. Treatment with IFN-beta induced the expression of CD123 in PDC and decreased the number of circulating MDC. These results suggest an impaired maturation state of DC in PPMS patients, and a beneficial effect of IFN-beta favouring the survival of PDC and promoting a Th2 environment.
我们研究了86例多发性硬化症（MS）患者和33名健康对照者（HC）循环髓样树突状细胞（MDC）和浆细胞样树突状细胞（PDC）的表型及频率。MS组包括20例原发性进展型MS（PPMS）患者、20例继发性进展型MS（SPMS）患者和46例复发缓解型MS（RRMS）患者[23例接受β干扰素（IFN-β）治疗]。通过流式细胞术分析循环MDC和PDC的频率以及CD83、CD123、CD80、CD86和CD40的表达。SPMS和PPMS患者循环MDC的百分比降低。PPMS患者中CD83、CD80和CD86的表达较低。IFN-β治疗诱导了PDC中CD123的表达，并减少了循环MDC的数量。这些结果表明PPMS患者中DC的成熟状态受损，且IFN-β具有有利于PDC存活并促进Th2环境的有益作用。
Zotero 插件